VBI Vaccines Inc. (NASDAQ:VBIV – Get Free Report) shares passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.61 and traded as low as $0.56. VBI Vaccines shares last traded at $0.60, with a volume of 123,634 shares changing hands.
Wall Street Analyst Weigh In
Separately, StockNews.com initiated coverage on VBI Vaccines in a report on Friday. They issued a “sell” rating on the stock.
Read Our Latest Stock Report on VBI Vaccines
VBI Vaccines Price Performance
About VBI Vaccines
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.
Featured Articles
- Five stocks we like better than VBI Vaccines
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- MarketBeat Week in Review – 4/22 – 4/26
- The How And Why of Investing in Oil Stocks
- 3 Stocks Leading the U.S. Agriculture Comeback
- NYSE Stocks Give Investors a Variety of Quality Options
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.